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Drug provocation tests (DPTs) are often needed when evaluating patients with suspected drug hypersensitivity
reactions. General considerations on DPTs, with regard to indications, contraindications, methods, limitations and
interpretations have been thoroughly addressed and various protocols are published. However, the field of drug
allergy is changing and DPTs make no exception. Novel (or sometimes, simply renewed) approaches arise, awaiting
to be either validated or refuted in larger studies in the future. Instead of covering the whole topic of DPTs, this
paper will address these recent and challenging aspects.
Keywords: Drug provocation test, Gold standard, Drug hypersensitivity reactionsBackground
Drug provocation test (DPT) comes at the end of a step-
wise approach in the drug allergy work-up. While there
is general agreement that it is the procedure that holds
the finest sensitivity amongst all the other available diag-
nostic tools, and that it may considerably improve pa-
tient management, its use as “gold standard” to establish
(rather than just to exclude) the diagnosis of drug hyper-
sensitivity reaction (DHR), is not unanimously accepted,
due to the reactions it may trigger, depending on the se-
verity of the index reaction.
Whether it is recommended by certain allergy societies
[1] or guidelines [2] and briefly mentioned or debated by
others [3], the decision of performing or not a DPT
should only be taken on a patient to patient basis, after
balancing the risk-benefit ratio in individual cases.
It cannot be disputed that DPTs represent a potential
risk to the patient, are time consuming and need appro-
priate medical facilities and trained personnel. They are,
however, sometimes the only resource available for con-
firmation or exclusion of hypersensitivity when previous
investigation steps are negative, non-conclusive or sim-
ply unavailable [2,4]. General considerations on DPTs,
with regard to indications, contraindications, methods,
limitations and interpretations have been thoroughly* Correspondence: pascal.demoly@inserm.fr
1Allergy unit, Hôpital Arnaud de Villeneuve, 371 Avenue du Doyen Giraud,
Montpellier 34295, France
2INSERM U657, University Hospital of Montpellier, Montpellier Cedex 5 34295,
France
© 2013 Chiriac and Demoly; licensee BioMed
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumaddressed [2] and protocols published [5-8]. Neverthe-
less, the precise challenge procedure may vary a lot from
one team to another and the need to standardize its
practice has not been met so far.
On the other hand, data emerging from different cen-
ters, using different strategies of testing, from indication
to interpretation of results, help move forward the field
of drug hypersensitivity in terms of classification, diag-
nosis, impact on quality of life. Recent publications tack-
ling DPTs have shown promising results, which await
confirmation in the future. Instead of covering the whole
topic of DPTs, this paper will address these recent and
challenging aspects. For more detailed reviews on how
to perform DPT, readers are referred to previously pub-
lished guidelines and reviews [2,4,9,10].Methodology of DPT
Dosage of test preparations and time intervals vary be-
tween published studies. A maximum single dose of the
specific drug must be achieved, and the administration
of the defined daily dose is desirable. Depending on the
type of drug itself, the severity of the DHR under investi-
gation and its mechanisms, the expected time latency
between application and reaction, DPT may take hours,
days or, occasionally, weeks, before completion [2]. The
evaluation of DHRs to beta-lactam antibiotics has raised
the issue of resensitization after a negative allergological
work-up (whether or not followed by full therapeutic
courses), and concerns were expressed mainly in relationCentral Ltd. This is an Open Access article distributed under the terms of the
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troversy amongst different groups on whether one full
therapeutic dose (of whatever tested drug) is sufficient
enough to elicit reactions in non-immediate responders.
Hence, full therapeutic courses have been suggested to
increase the sensitivity of DPTs. However, such an indi-
cation is still under debate and must be regarded cau-
tiously, in terms of diagnostic improvement, cost and
medical implications. Hjortlund et al. [11] conducted a
7-day oral treatment for patients with an initial negative
work-up (comprising IgE, skin tests and a single chal-
lenge protocol), according to the European Network for
Drug Allergy (ENDA guidelines) [5,7]. 23 patients (i.e.,
5.7% of the 405 tested) were found to develop a reaction
during the subsequent 7-day challenge with oral penicil-
lin. Interestingly, the time interval to the occurrence of
the clinical reaction in these patients was longer in most
cases than that reported in the case history, which is in
contrast to other studies in which it is shorter [12]. An-
other point worth mentioning is that intradermal tests
were performed at lower concentrations than those
recommended (i.e., 1.25 mg/ml). Thus, whether or not
some of these 23 patients might have actually displayed
positive skin tests at higher, recommended concentra-
tions, therefore being diagnosed by means of skin testing
and not DTP, might be questioned.
The scientific value associated to diagnostic DPT
DPT is considered the “gold standard” in the diagnosis
of DHR to many drugs including nonsteroidal anti-
inflammatory drugs (NSAIDs), due to the absence of re-
liable skin tests (or in-vitro tests), except for certain IgE
mediated reactions. Because of a variety of clinical pres-
entation of NSAIDs DHR (respiratory, cutaneous or ana-
phylaxis, and single or multiple reactors) [13], reliability
of clinical history is difficult to assess, and most patients
require DPT to confirm or refute diagnosis. The upmost
interest of a DPT is to rule out the responsibility of a
drug. Indeed, in our pioneer work [6] involving 1372
DPTs performed using various drugs, including ß-
lactams (30.3%), aspirin (14.5%), other NSAIDs (11.7%),
paracetamol (8.9%), macrolides (7.4%), and quinolones
(2.4%), there were only 241 (17.6%) positive results.
While being a diagnostic tool, confirming the role of
NSAIDs in 13.4% [14] to 85.7% [15] of the suspicions,
DPT holds an intrinsic scientific value, since it generates
precious knowledge. In this respect, we [16] used data
collected from a large database in 980 patients gathered
over a 10-year period (using both the clinical history and
the results of the DPTs) to put forward a new classifica-
tion of NSAIDs DHR. The objective was to demonstrate
whether or not patterns of NSAIDs reactivity are well
defined with little or no overlap and to have the possibil-
ity of identifying patients at a high risk, with a ratherhigh probability, according to clinical history and clinical
manifestations. Based on our cohort of 122 (12.5%) posi-
tive patients, accounting for 307 positive DPTs and 105
negative challenges for finding an alternative drug, we
were able to design a new classification, encompassing
all our patients (some of which could not be included in
the groups previously described by others) [13,14,17].
We chose to group the conditions comprising asthma/
rhinosinusitis and/or urticaria/angioedema in one single
entity of underlying diseases, because we noticed that
the same clinical forms, i.e. immediate reactions (occur-
ring immediately or up to 6 h after drug exposure) such
as asthma/rhinitis and/or urticaria/angioedema can be
seen with or without any underlying disease. Another
major clinical innovation of our analysis is the highlight-
ing of non-immediate angioedema (occurring between 6
to 24 h after exposure) as a form of non-immediate reac-
tion to NSAIDs, which was not included in the previous
classifications. This classification provides immediate ap-
plication in clinical practice, since it offers an insight
into the management of these patients, making it easier
to decide which steps need to be followed to choose the
drug to be tested (same drug, alternative drug from an-
other NSAID family, or a COX-2 inhibitor directly).
Peculiar aspects of drug allergy work-up in children
Studies comparing proven DHRs prevalence among differ-
ent age populations are scarce and a recent study of ours
[18] addresses this issue. We found a similar rate of proven
DHRs in children and adult groups when anaphylaxis, ana-
phylactic shock, urticaria/angioedema were the suspected
clinical manifestations (comprising 20%, 30% and 10% of
the cases respectively). In maculopapular exanthemas,
however, a remarkable difference of proven reactions was
found between the two (3.1% in children vs. 12.8% in
adults). This reinforces the fact that maculopapular exan-
themas in children are not usually due to drugs and should
clearly be differentiated from urticaria.
In children treated with beta-lactams, skin eruptions,
mostly described as maculopapular or urticarial, are fre-
quently assumed to be a drug-related allergy, although it
has been suggested that most of these eruptions are ac-
tually not allergic in nature, with viral infections being
often considered as the differential diagnosis, although
the role of virus-drug specific T cell interactions still
needs to be worked out. In a prospective study, Caubet
et al. [19] conducted DPTs, irrespective of skin test re-
sults, in a population of 88 children with delayed-onset
benign eruptions occurring during treatment with beta-
lactam antibiotic. Based on the observation that none of
the patients developed an immediate and/or a severe re-
action during DPT, the authors suggest that a 1-dose
DPT in children with a history of a delayed-onset benign
reaction (assessed by a careful primary evaluation in the
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ered safe. Although tempting, this approach needs valid-
ation in larger studies.
There is a general consensus amongst allergy societies
about the contraindications of DPT, with respect to the se-
verity of the initial reaction and the availability of immedi-
ate treatment allowing complete and fast recovery [2,3].
DPT should never be performed on patients who have ex-
perienced severe, life-threatening immunocytotoxic reac-
tions, vasculitic syndromes, exfoliative dermatitis, erythema
multiforme major/Stevens-Johnson syndrome, drug in-
duced hypersensitivity reactions (with eosinophilia)/DRESS,
toxic epidermal necrolysis or organ involvements. However,
the US Practice Parameters [3] state that rare exceptions to
this may exist, such as treatment of a life-threatening ill-
ness, in which case the benefit of treatment outweighs the
risk of a potentially life-threatening reaction. In a large
retrospective study regarding beta-lactam allergy in chil-
dren, Ponvert et al. [20] suggest that serum-sickness like
reactions, erythema multiforme, and Stevens-Johnson syn-
drome in children are mainly due to viral infections, and in
such patients, with a negative allergological work-up based
on non-immediate reading intradermal and patch tests,
DPT might be considered for essential (future necessity)
beta-lactams. However, this attitude must be regarded
with the uttermost caution, since evidence supporting it
is lacking and due to the high risk of recurrence of such
reactions [21].
DPT as a systematic diagnostic tool in non-immediate
cutaneous hypersensitivity reactions to iodinated radio-
contrast media (iRCM)
A recent European multicenter study [22] showed that
patients with non-immediate iRCM allergy exhibit ex-
tensive skin tests cross-reactivity amongst different
iRCM. Identification of a well-tolerated alternative iRCM
is important once the allergy diagnosis has been
established. However, the value of skin testing is limited
in non-immediate reactors [23], as opposed to immedi-
ate reactors [24]. Based on their experience with the
largest series of patients (161) published so far in non-
immediate DHR to iRCM, undergoing a complete
allergological work-up (including both skin and provoca-
tion tests), Torres et al. [12] recently suggested that
DPT be used not only as a diagnostic tool in such pa-
tients, but also to certify tolerance of an alternative skin
test-negative iRCM. Their data confirm that skin-test
sensitivity in non- immediate reactors is insufficient,
even using maximal concentrations (ie, intradermal test
with undiluted iRCM), since more than half of the cases
needed a DPT to be diagnosed. Moreover, in the group
of patients with a positive skin test, tolerance could not
be guaranteed to an alternative iRCM from a negative
skin test, as DPT was positive in 32.3% of the patients.DPT as a diagnostic tool in the evaluation of
perioperative anaphylaxis
DPTs have limited indications in perianesthetic anaphyl-
axis, since they are contraindicated with many anesthetics,
such as muscle relaxants [25]. The guidelines on periopera-
tive anaphylaxis of the French Society of Anesthesia and
Resuscitation, endorsed by ENDA and the Drug Allergy
Interest Group of the European Academy of Allergology
and Clinical Immunology [25] recommend DPTs with
drugs for which skin tests cannot be conducted or when
skin tests are negative (local anesthetics, antibiotics) or not
validated (NSAIDs, paracetamol). For general anesthetics,
this gold standard allergy test cannot normally be used be-
cause of the pharmacological effects of these drugs. How-
ever, in the Danish Anesthesia Allergy Centre, such DPTs
are extensively used. Nevertheless, some suspected drugs
are only tested by administering up to maximum of one
tenth of the therapeutic dose. This approach allows the
diagnosis of DHRs such as dextrans (IgE-mediated mech-
anism) to be made and reduces the risk of both false posi-
tive test results (i.e., to low-molecular-weight heparins) and
false-negative test results (i.e., to opioids). Muscle relaxants
are not tested [26].
Patient reported outcomes (PROs) in drug allergy
Questionnaires regarding satisfaction on DTP
The assessment of PROs has gained increasing importance
over the last years, with investigators using different kind
of surveys to obtain data collection. The drug allergy field
makes no exception. The impact of diagnostic tools such
as DPT has not been considered from the patient’s per-
spective until recently. 217 patients that underwent DPT
for diagnostic purposes in 3 European centers were asked
to fill in a questionnaire focused on the perceived advan-
tages/disadvantages of the DPT and on the general satis-
faction with the test. Data collected revealed that most
patients accepted DPT for diagnostic purpose irrespective
of the test final results, and 95% of them believed that it
was useful and they would recommend it to others [27].
Similar findings were observed across centres, in adults as
well as in children.
Negative predictive value (NPV) of DPTs
Though not completely established, the NPV of DPTs is
important for both the patient and the physician. They
both have to know whether a reaction can occur after tak-
ing a drug, which tested negatively. This information
should reassure the patients and their doctors in prescrib-
ing drugs with negative DPT. However, even despite nega-
tive DPTs, a third of our patients were afraid of a potential
reaction and did not take the negatively tested drug after-
wards [28] and in a sixth of them, physicians refused to
prescribe the negatively tested NSAID and preferred an al-
ternative, as previously described with ß-lactam [29].
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other test procedures, it has its limitations. A negative test
does not prove beyond any doubt tolerance for the drug
in the future, but rather that there is no DHR at the time
and conditions of the challenge. Indeed, IgE sensitivity
may decrease over time [8], co-factors such as food, exer-
cise, or viral infections may have been missed. Studies re-
garding the NPV of DPTs are encouraging. A high NPV of
beta-lactam DPT of 94-98% was found in large studies in-
volving 256 children [30] and 457 patients (both adults
and children) [31] and most of the reactions reported by
patients were mild non-immediate reactions. As for the
antibiotics, the NPV of DPTs with NSAIDs appears to be
also high (over 96%) whatever the NSAID (the one nega-
tively tested or an alternative), and none of the false-
negative patients described a life-threatening reaction
[31]. The working hypothesis regarding our high NPV is
that we finish our DPT with a high dose (as close to the
'cumulative daily dose' as possible) and this may be the
reason why some recent studies [11], finishing their proto-
col with only 'one unit dose', have shown that extension of
DPT protocol to one week leads to higher sensitivity.
Conclusion
Whether the point of interest of the different groups
working in the drug allergy field moves from the medical
(indications/contraindications, results) to the technical
(methodology) aspects of DPTs, or even addresses the pa-
tients perspective (PROs, satisfaction, NPV), the disclos-
ure of such challenging and various results can only
improve patient management. It remains to be seen which
of these novel approaches will stand the test of time, and
receive validation by larger studies.
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